Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation
暂无分享,去创建一个
Gabriele Gillessen-Kaesbach | Dagmar Wieczorek | Albert David | Kenji Kurosawa | Yoichi Matsubara | Nobuhiko Okamoto | Shigeru Tsuchiya | Tatsuya Ando | Shigeo Kure | Alain Verloes | Seiji Mizuno | Fumio Takada | Hélène Cavé | Pablo Lapunzina | H. Cavé | N. Philip | D. Wieczorek | P. Lapunzina | A. Verloes | H. Ohashi | Y. Matsubara | N. Okamoto | T. Niihori | Y. Aoki | G. Gillessen‐kaesbach | S. Mizuno | S. Kure | K. Kurosawa | A. David | H. Kawame | S. Tsuchiya | F. Takada | Tetsuya Niihori | Yoko Aoki | Tomoko Kobayashi | Nicole Philip | Takako Ohata | Hirofumi Ohashi | Hiroshi Kawame | Satoru Sakazume | S. Sakazume | T. Ando | Tomoko Kobayashi | I. Fujiwara | Yoko Narumi | Afag Guliyeva | Ikuma Fujiwara | Noriko Nakagawa | Antonio G Meneses | N. Nakagawa | Y. Narumi | T. Ohata | A. G. Meneses | Afag Guliyeva | A. Guliyeva | G. Gillessen‐Kaesbach
[1] Koichi Tabayashi,et al. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome , 2008, Journal of Human Genetics.
[2] B. Gelb,et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. , 2006, American journal of human genetics.
[3] J. Ko,et al. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype–phenotype correlation in Korean patients with Noonan syndrome , 2008, Journal of Human Genetics.
[4] M. Digilio,et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. , 2002, American journal of human genetics.
[5] J. Hussain,et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. , 2008, Molecular cell.
[6] G. Thomas,et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype , 2007, Nature Genetics.
[7] R. Hennekam. Costello syndrome: An overview , 2003, American journal of medical genetics. Part C, Seminars in medical genetics.
[8] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[9] G. Ferrero,et al. Clinical and molecular characterization of 40 patients with Noonan syndrome. , 2008, European journal of medical genetics.
[10] Judith G. Hall,et al. Noonan syndrome: the changing phenotype. , 1985, American journal of medical genetics.
[11] W. Kress,et al. Genotype-phenotype correlations in Noonan syndrome. , 2004, The Journal of pediatrics.
[12] Yukichi Tanaka,et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.
[13] Li Li,et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome , 2007, Nature Genetics.
[14] Wendy Schackwitz,et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.
[15] Pablo Rodriguez-Viciana,et al. Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.
[16] F. Lo,et al. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature , 2009, European Journal of Pediatrics.
[17] J. Opitz,et al. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome. , 1986, American journal of medical genetics.
[18] B. Neel,et al. Stops along the RAS pathway in human genetic disease , 2006, Nature Medicine.
[19] Walter Kolch,et al. Phosphatase and Feedback Regulation of Raf-1 Signaling , 2007, Cell cycle.
[20] M. Schimek,et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. , 2006, Cancer research.
[21] H. Ropers,et al. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.
[22] C. Pritchard,et al. Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.
[23] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[24] R. Marais,et al. 14-3-3 Antagonizes Ras-Mediated Raf-1 Recruitment to the Plasma Membrane To Maintain Signaling Fidelity , 2002, Molecular and Cellular Biology.
[25] D. Horn,et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome , 2007, Journal of Medical Genetics.
[26] Bruce D Gelb,et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.
[27] J. Opitz,et al. Noonan syndrome: a review. , 1985, American journal of medical genetics.
[28] M. Patton,et al. Genotypic and phenotypic characterization of Noonan syndrome: New data and review of the literature , 2005, American journal of medical genetics. Part A.
[29] R. Hennekam,et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.
[30] Michael J Ackerman,et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.
[31] Y. Matsubara,et al. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders , 2008, Human mutation.
[32] Stefan Mundlos,et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations , 2006, Journal of Medical Genetics.